ESTRO 35 Programme book

Symposium NEWCONCEPTS OF TUMOUR RADIORESISTANCE 09:15 - 10:30 | ROOM 2

The session will address tumour radioresistance in relation to cancer stem cells, immunology and next generation sequencing. The talks will cover: 1) evidence that radiotherapy can cause immunogenic cell death and that combined radiotherapy and immunotherapy can cause systemic long-term effects. 2) Evidence that cancer stem cells are radioresistant and that DNA damage response inhibitors can overcome the radioresistance and have therapeutic potential. 3) The potential of molecular profiling by next-generation sequencing for dissecting mechanisms of resistance to radiotherapy/chemoradiation, as exemplified by results from a recent multicenter trial in locally advanced head and neck cancer.

TUESDAY 3 MAY 2016

Chair: R. Syljuasen (Norway) Co-chair: R. Santoni (Italy)

09:15 > Radiotherapy combined with immunotherapy: present status and future perspectives Speaker: P. Lambin (The Netherlands)

SP-0575

09:40 > The contribution of cancer stem cells to tumour radioresistance Speaker: A. Chalmers (UK)

SP-0576

10:05 > Novel insights in radioresistance of head and neck cancer Speaker: I. Tinhofer-Keilholz (Germany)

SP-0577

Symposium with Proffered Papers TOWARDS PERSONALISED RADIATION ONCOLOGY (PRO) 09:15 - 10:30 | ISTANBUL

Personalised Radiation Oncology (PRO), integrating omics technology, is a rapidly developing concept that will have an enormous impact on radiation therapy in the near future. Besides fascinating science PRO brings also major new challenges before the concept can be successfully translated into the clinic, e.g. understanding the potential and limitations of modern omics technologies, interpretation of results and integration with established clinical parameters to personalise treatment. In this session we will inform and discuss about developments in genomics, results from studies using gene expression profiles and data integration approaches. We aim for interdisciplinary audience, i.e. the presentations will be understandable also for non-experts. In addition, we will discuss where we are today (ready for implementation?) or what needs to be done to accelerate translation of PRO into the clinics. Chair: D. Zips (Germany) Co-chair: V. Tombolini (Italy)

09:15 > New technologies for genomic tumour profiling Speaker: W. Weichert (Germany)

SP-0578

09:30 > Gene expression profiles in tumours for PRO Speaker: J. Alsner (Denmark)

SP-0579

INTERDISCIPLINARY RADIOBIOLOGY INTERDISCIPLINARYWITHRADIOBIOLOGYFOCUS

CLINICAL BRACHYTHERAPY PHYSICS

RTT

YOUNG

SCIENTIFIC PROGRAMME | PROGRAMME AND EXHIBITION GUIDE

150

PROGRAMME & EXHIBITION GUIDE

150

ESTRO 33